General Electric Co. (GE: Quote) said that data presented at the Society for Nuclear Medicine or SNM Annual Meeting shows that uptake of the investigational imaging agent [18F]flutemetamol correlates with a beta amyloid in vivo1biopsy and can be quantified using a PET-only registration method. Data from other studies show that [18F]flutemetamol uptake is inversely related to measures of cognitive function in non-demented older adults.
Additionally, the [18F]flutemetamol dosimetry profile is comparable to that of most PET diagnostic radiopharmaceuticals4 and the biodistribution attributes in Japanese and Caucasian subjects is comparable. [18F]Flutemetamol is a PET imaging agent in development for the detection of beta amyloid, which could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer's disease or AD, General Electric noted.
The company noted that the accumulation of beta amyloid in the brain is believed to play a role in the degeneration of neurons in AD and is one of several pathological characteristics implicated in its development. Currently, AD is confirmed by histopathological identification of core features, including beta amyloid plaques, in postmortem brain samples. Targeted amyloid imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in living humans.
| || |
| To receive FREE breaking news email alerts for General Electric Co and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com